Given that the upregulation of SNHG25 significantly enhances cancer cell invasiveness, two drugs, dabrafenib_1373 and OSI-027_1594, which exhibit significant negative correlations with SNHG25 expression, were screened as therapeutic candidates. The gene discussed is SNHG25; the disease is cancer.